Physician

Jeffrey Blake Hart, M.D.

According to 2025 Medicare claims, Jeffrey Hart, M.D. (NPI: 1770841967) practices internal medicine in the Longview, TX market, with the plurality of this provider's patient population coming from Gregg, TX. This provider's primary affiliated billing organization is ASSOCIATED CLINICIANS OF EAST TEXAS (NPI: 1932640349; TIN: 352585434) and primary practice location at 75605-2411. Hart is affiliated with the Prime Care Managers, LLC (ACO ID: A3280) and CHSPSC ACO 8, LLC (ACO ID: A3715), participating under the MSSP model.

Hart's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 871 traditional Medicare patients, billed 26,006 HCPCS/CPT codes, and received $561,905 in Medicare payments. The top billing code was 84443 (Blood test, thyroid stimulating hormone (tsh)). Part D data shows 22,618 prescription claims across 1,325 beneficiaries totaling $1,842,058 in drug costs, led by Eliquis (Apixaban). DME data shows 1,144 claims. Open Payments data shows 92 records totaling $1,397. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $54,414 to $561,905. Similarly, Part D prescription costs have risen steadily, from $44,597 to $1,842,058. In contrast, DME billing represents a smaller volume and rose steadily, from $9,442 to $74,882.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	179	1,431	$54,414
2016	626	7,180	$224,728
2017	706	13,283	$300,628
2018	774	22,806	$357,422
2019	821	19,119	$395,039
2020	819	19,627	$387,118
2021	1,014	28,391	$467,838
2022	904	20,347	$453,206
2023	887	22,460	$528,385
2024	871	26,006	$561,905

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	162	898	$44,597
2016	470	5,378	$357,907
2017	763	10,224	$745,546
2018	934	14,400	$1,120,323
2019	1,038	17,172	$1,346,625
2020	1,102	18,459	$1,451,792
2021	1,271	20,621	$1,663,154
2022	1,240	20,866	$1,627,311
2023	1,258	21,327	$1,794,648
2024	1,325	22,618	$1,842,058

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	40	135	$3,693
2017	82	428	$9,653
2018	199	662	$17,869
2019	259	788	$23,630
2020	304	876	$42,125
2021	218	690	$51,409
2022	204	732	$45,179
2023	311	836	$57,018
2024	357	1,144	$75,159

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
84443	Blood test, thyroid stimulating hormone (tsh)	756	941	$16
80061	Blood test, lipids (cholesterol and triglycerides)	776	1,043	$13
80053	Blood test, comprehensive group of blood chemicals	776	1,009	$10
36415	Insertion of needle into vein for collection of blood sample	806	1,247	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	772	1,033	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	242	14,767	$282,522
Ozempic	Semaglutide	194	6,972	$217,862
Jardiance	Empagliflozin	122	8,493	$152,205
Mounjaro	Tirzepatide	97	2,912	$99,709
Trulicity	Dulaglutide	61	2,218	$68,409

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	19	64	$31,209
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	N/R	12	$9,166
E0601	Continuous positive airway pressure (cpap) device	Y	29	168	$5,279
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	65	$4,518
A7032	Cushion for use on nasal mask interface, replacement only, each	N	21	46	$3,786

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	92	$1,397	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeffrey Blake Hart, M.D.?

Tedicare shows public-source Medicare data for Jeffrey Blake Hart, M.D. (NPI 1770841967), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeffrey Blake Hart, M.D. have ACO affiliation data?

Jeffrey Blake Hart, M.D. is shown with ACO affiliation data for Prime Care Managers, LLC (MSSP, ACO ID A3280) and CHSPSC ACO 8, LLC (MSSP, ACO ID A3715).

What billing organization is linked to Jeffrey Blake Hart, M.D.?

Jeffrey Blake Hart, M.D. is linked to ASSOCIATED CLINICIANS OF EAST TEXAS (billing NPI 1932640349) in the available physician profile data.

Does Jeffrey Blake Hart, M.D. have Open Payments data?

Jeffrey Blake Hart, M.D. has 92 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.